A recent pilot study at Be Well Hospital in Chennai, India, has found that Nichi-BRITE Beta glucans, a unique food supplement derived from the AFO-202 strain of Aureobasidium Pullulans, may hold the key to improving the lives of Parkinson’s disease patients. The study observed significant enhancements in patients’ Unified Parkinson’s Disease Rating Scale (UPDRS) and constipation scores after a 90-day regimen of Nichi-BRITE.
Parkinson’s disease, a debilitating neurological disorder, affects millions of people worldwide. An increasing body of research is uncovering the vital connection between gut health and neurological conditions like Parkinson’s. Nichi-BRITE Beta glucans have demonstrated the ability to regulate harmful gut bacteria while fostering the growth of beneficial microbiota.
Dr. Dedeepiya, one of the study’s authors, expressed optimism about Nichi-BRITE’s potential as a supplementary therapy for synucleinopathies, including Parkinson’s disease and multiple system atrophy. Dr. Nithyanandam, the study’s neurologist, stressed the need for further exploration through larger, in-depth studies to assess Nichi-BRITE’s full potential.
During a World Parkinson’s Day webinar, Prof. Muralidhar Hegde of Houston Methodist Research, USA, spoke about the critical role of alpha-synuclein abnormalities in the development of neurodegenerative diseases. Dr. Rukmini Mridula from Hyderabad highlighted the rise in young-onset Parkinson’s disease cases in India.
The promising findings from this pilot study suggest that Nichi-BRITE Beta glucans could become an essential component in combating Parkinson’s disease, offering renewed hope for millions of patients across the globe.
